论文部分内容阅读
目的探讨双水平无创正压通气(B iPAP)治疗慢性阻塞性肺疾病(COPD)急性加重期呼吸衰竭的价值。方法将39例COPD急性加重期合并呼吸衰竭患者随机分为治疗组和照组,对照组19例,采用常规药物综合治疗,治疗组20例,采用常规药物综合治疗加无创正压通气。结果治疗组患者心率、呼吸困难、血气分析改善情况及平均住院时间均优于对照组,2组比较差异有统计学意义(P<0.01或P<0.05),平均住院日分别为(14±5)d和(19±6)d(P<0.01);需气管插管有创通气者分别为3例(15.0()和4例(21.1()(P>0.05)。结论双水平无创正压通气可迅速缓解COPD急性加重期呼吸衰竭病人的临床症状,提高PaO2和降低PaCO2,缩短住院时间,是治疗呼吸衰竭的有效手段。
Objective To investigate the value of BipAP on respiratory failure in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods Thirty-nine patients with acute exacerbation of COPD and respiratory failure were randomly divided into treatment group and control group, and control group (n = 19). The patients in the control group were treated with conventional drugs. The treatment group (n = 20) was treated with conventional drug therapy combined with non-invasive positive pressure ventilation. Results The heart rate, dyspnea, improvement of blood gas analysis and average length of stay in the treatment group were better than those in the control group. There was significant difference between the two groups (P <0.01 or P <0.05), and the average length of hospital stay was (14 ± 5) ), d (19 ± 6) d and (19 ± 6) d respectively (P <0.01) .The patients with invasive ventilation required tracheal intubation were 3 (15.0) and 4 (21.1) Ventilation can quickly relieve the clinical symptoms of COPD patients with respiratory failure, increase PaO2 and reduce PaCO2, shorten the hospital stay, is an effective means of treatment of respiratory failure.